Rheumatology Advance Access published online on September 20, 2004
Rheumatology, doi:10.1093/rheumatology/keh404
Rheumatology © British Society for Rheumatology 2004; all rights reserved
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Clinical Immunology, Third Department of Internal Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary; Second Department of Pediatrics, Faculty of Medicine, Semmelweis University, Budapest, Hungary
* To whom correspondence should be addressed. E-mail: ponyi{at}gyer2.sote.hu.
Objectives. To present the outcome of patients with idiopathic inflammatory myositis, focusing on functional ability and quality of life. Methods. Analysis was performed using data from 105 adult patients with definitive polymyositis, dermatomyositis or overlap myositis, who were followed up at a single centre. The diagnosis was made between 1979 and 2000 based on Bohan and Peter's criteria. Functional ability was assessed after a minimum follow-up of 3 yr with the Health Assessment Questionnaire Disability Index (HAQDI) and quality of life was measured with the Short Form 36-item questionnaire (SF-36). Results. Fifteen patients in our cohort died and 87 participated in the evaluation of functional outcome. Functional ability after a median follow-up of 107.1 months (range 36.4-273.3) was heterogeneous. The median HAQDI score was 0.875 (range 0-2.875). Polyphasic or chronic-progressive disease course, osteoporosis and long-term follow-up were predictive of higher HAQDI scores. In terms of quality of life, significant differences from population norms were shown in all domains of the SF-36. There were no significant differences in the SF-36 scores among the patients according to clinicopathological subset or disease course. Conclusions. Although the mortality of our cohort was favourable, myositis continues to have a great impact on life in the medium and long term. The present work indicates that myositis patients have a significantly poorer quality of life than the normal population, but there was no difference among the patients according to clinicopathological subsets.
Accepted August 10, 2004
Original Papers
Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis
2 Second Department of Pediatrics, Faculty of Medicine, Semmelweis University, Budapest, Hungary
3 Division of Clinical Immunology, Third Department of Internal Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. O. Harris-Love, J. A. Shrader, D. Koziol, N. Pahlajani, M. Jain, M. Smith, H. L. Cintas, C. L. McGarvey, L. James-Newton, A. Pokrovnichka, et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis Rheumatology, February 1, 2009; 48(2): 134 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I M Bronner, M F G van der Meulen, M de Visser, S Kalmijn, W J van Venrooij, A E Voskuyl, H J Dinant, W H J P Linssen, J H J Wokke, and J E Hoogendijk Long-term outcome in polymyositis and dermatomyositis Ann Rheum Dis, November 1, 2006; 65(11): 1456 - 1461. [Abstract] [Full Text] [PDF]
|
|